ACTL6A: Difference between revisions

Latest revision as of 22:29, 15 December 2024

ACTL6A

ACTL6A (Actin-like protein 6A) is a protein encoded by the ACTL6A gene in humans. This protein is a member of the actin-related protein family and plays a crucial role in chromatin remodeling, which is essential for the regulation of gene expression.

Function[edit]

ACTL6A is involved in the SWI/SNF chromatin remodeling complex, which is responsible for altering the structure of chromatin to allow access to DNA for transcription, replication, and repair. The protein acts as a core component of this complex, contributing to its ability to modify chromatin structure and regulate gene expression.

The SWI/SNF complex, with ACTL6A as a part, is known to be involved in various cellular processes, including cell cycle regulation, differentiation, and development. It is also implicated in the response to DNA damage and the maintenance of genomic stability.

Clinical Significance[edit]

Mutations or dysregulation of ACTL6A have been associated with several types of cancer, including breast cancer, lung cancer, and glioblastoma. The protein's role in chromatin remodeling makes it a critical factor in the control of genes that regulate cell proliferation and survival, which are often disrupted in cancer.

Research has shown that ACTL6A can influence the epithelial-mesenchymal transition (EMT), a process that is crucial for cancer metastasis. Overexpression of ACTL6A has been linked to poor prognosis in cancer patients, making it a potential target for therapeutic intervention.

Interactions[edit]

ACTL6A interacts with several other proteins within the SWI/SNF complex, including BRG1, BRM, and BAF155. These interactions are essential for the assembly and function of the chromatin remodeling complex.

Research[edit]

Ongoing research is focused on understanding the precise mechanisms by which ACTL6A contributes to chromatin remodeling and its role in disease. Studies are also exploring the potential of targeting ACTL6A in cancer therapy, given its involvement in tumor progression and metastasis.

Also see[edit]

This protein-related article is a stub. You can help WikiMD by expanding the page.

@@ Line 1: / Line 1: @@
-<br>= ACTL6A =
+ACTL6A
-== Introduction ==
+'''ACTL6A''' (Actin-like protein 6A) is a protein encoded by the '''ACTL6A''' gene in humans. This protein is a member of the actin-related protein family and plays a crucial role in chromatin remodeling, which is essential for the regulation of gene expression.
-ACTL6A, also known as Actin-like protein 6A, is a protein encoded by the ACTL6A gene in humans. It is a member of the actin-related protein family and plays a crucial role in chromatin remodeling, which is essential for regulating gene expression. ACTL6A is involved in various cellular processes, including cell proliferation, differentiation, and development.
-== Gene and Protein Structure ==
-The ACTL6A gene is located on chromosome 3 at the cytogenetic band 3q26.33. The gene spans approximately 50 kilobases and consists of multiple exons. The protein product of ACTL6A is composed of 424 amino acids and has a molecular weight of approximately 47 kDa.
-ACTL6A shares structural similarities with conventional actins but has distinct functions. It contains an actin-like domain that is involved in binding to other proteins and DNA, facilitating its role in chromatin remodeling complexes.
 == Function ==
-ACTL6A is a component of the SWI/SNF chromatin remodeling complex, which is responsible for altering the structure of chromatin to regulate access to DNA. This process is vital for the transcriptional activation or repression of genes. ACTL6A, in particular, is known to interact with other proteins such as BRG1 and BAF155, which are core components of the SWI/SNF complex.
+ACTL6A is involved in the [[SWI/SNF chromatin remodeling complex]], which is responsible for altering the structure of chromatin to allow access to DNA for transcription, replication, and repair. The protein acts as a core component of this complex, contributing to its ability to modify chromatin structure and regulate gene expression.
-The protein is involved in various biological processes, including:
+The SWI/SNF complex, with ACTL6A as a part, is known to be involved in various cellular processes, including [[cell cycle]] regulation, [[differentiation]], and [[development]]. It is also implicated in the response to [[DNA damage]] and the maintenance of [[genomic stability]].
-* '''Cell Cycle Regulation:''' ACTL6A plays a role in controlling the progression of the cell cycle, particularly during the G1/S transition.
-* '''Neuronal Development:''' It is crucial for the development and differentiation of neural progenitor cells.
-* '''Cancer:''' Dysregulation of ACTL6A expression has been implicated in several cancers, including glioblastoma and breast cancer, where it may contribute to tumor progression and metastasis.
 == Clinical Significance ==
-Alterations in the expression or function of ACTL6A have been associated with various diseases. Overexpression of ACTL6A has been observed in certain types of cancer, suggesting it may serve as a potential biomarker for diagnosis or prognosis. Additionally, targeting ACTL6A or its associated pathways could provide therapeutic benefits in cancer treatment.
+Mutations or dysregulation of ACTL6A have been associated with several types of [[cancer]], including [[breast cancer]], [[lung cancer]], and [[glioblastoma]]. The protein's role in chromatin remodeling makes it a critical factor in the control of genes that regulate cell proliferation and survival, which are often disrupted in cancer.
+Research has shown that ACTL6A can influence the [[epithelial-mesenchymal transition]] (EMT), a process that is crucial for cancer metastasis. Overexpression of ACTL6A has been linked to poor prognosis in cancer patients, making it a potential target for therapeutic intervention.
-Research has also indicated that ACTL6A may play a role in neurodevelopmental disorders, although further studies are needed to elucidate its exact contributions.
+== Interactions ==
+ACTL6A interacts with several other proteins within the SWI/SNF complex, including [[BRG1]], [[BRM]], and [[BAF155]]. These interactions are essential for the assembly and function of the chromatin remodeling complex.
-== Research and Future Directions ==
+== Research ==
-Ongoing research aims to better understand the precise mechanisms by which ACTL6A influences chromatin dynamics and gene expression. Studies are also exploring the potential of ACTL6A as a therapeutic target, particularly in oncology.
+Ongoing research is focused on understanding the precise mechanisms by which ACTL6A contributes to chromatin remodeling and its role in disease. Studies are also exploring the potential of targeting ACTL6A in cancer therapy, given its involvement in tumor progression and metastasis.
-Future research directions include:
+== Also see ==
-* '''Elucidating Molecular Interactions:''' Detailed studies on the interactions between ACTL6A and other chromatin remodeling proteins.
+* [[Chromatin remodeling]]
-* '''Functional Studies in Development:''' Investigating the role of ACTL6A in embryonic development and stem cell differentiation.
+* [[SWI/SNF complex]]
-* '''Therapeutic Targeting:''' Developing small molecules or biologics that can modulate ACTL6A activity in disease contexts.
+* [[Gene expression regulation]]
+* [[Cancer biology]]
-== Conclusion ==
+{{Protein-stub}}
-ACTL6A is a pivotal component of the chromatin remodeling machinery, with significant implications for cell biology and disease. Understanding its functions and regulatory mechanisms offers promising avenues for therapeutic intervention in cancer and other diseases.
-== References ==
+[[Category:Proteins]]
-* [1] Smith, J. et al. (2020). "The Role of ACTL6A in Chromatin Remodeling and Cancer." *Journal of Molecular Biology*, 432(15), 1234-1245.
+[[Category:Human genes]]
-* [2] Johnson, L. et al. (2019). "ACTL6A: A Key Player in Neural Development and Disease." *Neuroscience Research*, 150, 45-53.
+[[Category:Chromatin remodeling]]
-* [3] Brown, A. et al. (2021). "Targeting ACTL6A in Cancer Therapy: Current Perspectives." *Cancer Treatment Reviews*, 95, 102-110.